RAC1 and cancer: Ras-related C3 botulinum toxin substrate 1 (Rac1) is a promising emerging target due to its critical role in cancer progression, as its dysregulation has been reported to be implicated in various forms of cancer (Liang et al., 2021; Ma et al., 2023).